Adaptimmune Therapeutics (ADAP) Financials

$0.04

$0.01 (17.50%)

As on 03-Dec-2025 09:30EDT

Market cap

$15 Mln

Revenue (TTM)

$65 Mln

P/E Ratio

--

P/B Ratio

2.7

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Operating Revenue	65.09	178.03	60.28	27.15	6.15	3.96
Cost of Revenue	9.13	0.07	9.86	127.73	111.09	91.57
Gross Profit	61.71	177.96	50.42	-100.58	-104.94	-87.61
Operating Expenses	225.93	246.72	188.42	191.11	168.40	137.36
Operating Profit (EBIT)	-164.22	-68.76	-138.04	-163.97	-162.25	-133.41
Other Income	--	--	--	--	3.85	1.16
Profit before Tax	-163.74	-67.27	-112.54	-162.96	-157.30	-129.93
Provision for Tax	0.74	3.58	1.34	2.50	0.79	0.16
Profit after Tax (Net Income)	-169.76	-70.81	-113.87	-165.46	-158.09	-130.09
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	-165.46	-158.09	-130.09

Liabilities ($ Mln)	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Shareholder's Funds	-70.96	11.85	39.51	81.88	205.96	341.23
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	150.08	169.59	170.32	182.54	201.04	70.84
Current Liabilities	51.51	64.53	72.79	64.50	62.54	39.07
Total Liabilities	182.15	245.96	282.62	328.92	469.55	451.14

Assets ($ Mln)	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Non-Current Assets	52.52	57.79	75.06	73.55	54.09	52.99
Current Assets	78.12	188.17	207.55	255.37	415.46	398.15
Total Assets	182.15	245.96	282.62	328.92	469.55	451.14
Total Debt*	48.68	74.21	25.24	23.08	25.47	23.71
Net Current Assets	26.60	123.64	134.76	190.87	352.92	359.08

Cashflow ($ Mln)	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Cash From Operating Activities	--	-73.21	-140.88	-141.77	10.73	-53.59
Cash Flow from Investing Activities	--	-58.95	176.54	89.14	75.80	-278.92
Cash from Financing Activities	--	78.75	0.88	12.87	3.29	340.05
Net Cash Inflow / Outflow	--	--	--	--	89.82	7.54

Financials Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Adjusted EPS ($)	-0.66	-0.28	-0.50	-1.01	-1.01	-0.84
Cash EPS ($)	--	-0.23	-0.46	-0.97	-0.97	-0.79
Adjusted Book Value ($)	--	0.05	0.17	0.50	1.32	2.20
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.29	-0.62	-0.86	0.07	-0.35
Free Cash Flow per Share ($)	--	-0.30	-0.64	-1.05	0.01	-0.37

Profitability Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
ROCE (%)	--	-93.91	-134.20	-98.37	-53.02	-50.62
ROE (%)	--	-275.74	-187.61	-114.96	-57.78	-55.97
ROA (%)	-57.95	-26.79	-37.24	-41.44	-34.34	-41.12
EBIT Margin (%)	-246.42	-35.89	-228.99	-595.49	-2,638.56	-3,372.01
Net Margin (%)	-260.82	-39.78	-188.90	-609.46	-1,580.74	-2,540.86
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Revenue Growth (%)	-53.99	1.95	1.22	3.42	0.55	2.53
EBIT Growth (%)	-99.65	53.71	14.61	0.36	-21.56	4.53
Net Profit Growth (%)	-132.81	37.81	31.18	-4.66	-21.52	5.16
EPS Growth (%)	-89.70	0.45	0.50	0.00	-0.20	0.36
Book Value Growth (%)	-172.53	--	--	--	--	--

Valuation Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Price / Earnings	--	-1.95	-1.58	-1.45	-3.71	-6.41
Price / Book Value	2.68	11.64	4.56	2.93	2.84	2.44
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-1.71	-1.15	-0.46	-0.37	-1.55	-3.89
Close Price ($)	0.24	0.54	0.79	1.46	3.75	5.39
High Price ($)	1.48	2.05	2.35	4.12	7.34	13.40
Low Price ($)	0.20	0.53	0.42	1.01	3.37	1.15
Market Cap ($ Cr)	14.55	--	--	--	--	--

Solvency Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Debt to Equity	-0.36	6.26	0.64	0.28	0.12	0.07
Short term debt to equity ratio	-0.13	0.79	0.14	0.07	0.02	0.01
Current Ratio	1.52	2.92	2.85	3.96	6.64	10.19
Quick Ratio	1.29	2.80	2.83	3.94	6.63	10.14
Interest Coverage	-27.90	-19.08	--	-160.70	-32.80	-38.41

Operating Efficiency Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Debtors to sales (%)	44.40	8.98	77.83	140.29	553.05	523.60
Asset Turnover	0.22	0.67	0.20	0.07	0.01	0.01
Receivable days	--	64.52	257.53	484.98	1,625.51	1,846.00
Inventory Days	--	22,564.62	48.32	2.90	4.66	7.07
Payable days	--	43,882.18	238.65	18.40	23.84	25.42
Cash Conversion Cycle	--	-21,253.03	67.20	469.48	1,606.32	1,827.65

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.